Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
VYGR's Cash-to-Debt is ranked higher than
68% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. VYGR: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
VYGR' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.33
VYGR's Equity-to-Asset is ranked lower than
80% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. VYGR: 0.33 )
Ranked among companies with meaningful Equity-to-Asset only.
VYGR' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.28  Med: 0.67 Max: 0.74
Current: 0.33
-0.28
0.74
Interest Coverage No Debt
VYGR's Interest Coverage is ranked higher than
60% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VYGR: No Debt )
Ranked among companies with meaningful Interest Coverage only.
VYGR' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -0.87
Beneish M-Score: -4.79
WACC vs ROIC
19.01%
106.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -1611.42
VYGR's Operating Margin % is ranked lower than
82% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. VYGR: -1611.42 )
Ranked among companies with meaningful Operating Margin % only.
VYGR' s Operating Margin % Range Over the Past 10 Years
Min: -1611.42  Med: -303.64 Max: -216.85
Current: -1611.42
-1611.42
-216.85
Net Margin % -1382.73
VYGR's Net Margin % is ranked lower than
81% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. VYGR: -1382.73 )
Ranked among companies with meaningful Net Margin % only.
VYGR' s Net Margin % Range Over the Past 10 Years
Min: -1382.73  Med: -226.92 Max: -171.18
Current: -1382.73
-1382.73
-171.18
ROE % -83.41
VYGR's ROE % is ranked lower than
68% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. VYGR: -83.41 )
Ranked among companies with meaningful ROE % only.
VYGR' s ROE % Range Over the Past 10 Years
Min: -83.41  Med: -51.66 Max: -26.36
Current: -83.41
-83.41
-26.36
ROA % -39.90
VYGR's ROA % is ranked lower than
57% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. VYGR: -39.90 )
Ranked among companies with meaningful ROA % only.
VYGR' s ROA % Range Over the Past 10 Years
Min: -280.22  Med: -31.22 Max: -19.18
Current: -39.9
-280.22
-19.18
ROC (Joel Greenblatt) % -792.16
VYGR's ROC (Joel Greenblatt) % is ranked lower than
56% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. VYGR: -792.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
VYGR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1245.05  Med: -1011.33 Max: -792.16
Current: -792.16
-1245.05
-792.16
3-Year EBITDA Growth Rate -46.00
VYGR's 3-Year EBITDA Growth Rate is ranked lower than
86% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. VYGR: -46.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
VYGR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -23 Max: -46
Current: -46
3-Year EPS without NRI Growth Rate 11.00
VYGR's 3-Year EPS without NRI Growth Rate is ranked higher than
56% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. VYGR: 11.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
VYGR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.5 Max: 11
Current: 11
0
11
GuruFocus has detected 2 Warning Signs with Voyager Therapeutics Inc VYGR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VYGR's 30-Y Financials

Financials (Next Earnings Date: 2019-03-15)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

VYGR Guru Trades in

Q1 2018

VYGR Guru Trades in Q1 2018

Jim Simons 211,565 sh (New)
» More
Q2 2018

VYGR Guru Trades in Q2 2018

Pioneer Investments 64,800 sh (New)
Jim Simons 95,600 sh (-54.81%)
» More
Q3 2018

VYGR Guru Trades in Q3 2018

Steven Cohen 101,975 sh (New)
Pioneer Investments Sold Out
Jim Simons 75,400 sh (-21.13%)
» More
» Details

Insider Trades

Latest Guru Trades with VYGR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Voyager Therapeutics Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:LJPC, SZSE:002286, SZSE:300705, XBRU:TIG, SZSE:300583, XKRX:084110, TSE:7774, NAS:KURA, OSTO:PROB, SZSE:300181, NAS:ACIU, TSE:2160, NAS:SRNE, NAS:BYSI, NAS:AMAG, NAS:ODT, NAS:ABEO, NAS:CHRS, NAS:RCKT, NAS:ARWR » details
Traded in other countries:VT6.Germany,
Headquarter Location:USA
Voyager Therapeutics Inc in collaboration with Genzyme, conducts research and development work to develop therapies for the treatment of central nervous system disorders. It targets diseases such as Parkinson's, Alzheimer's Huntington's.

Voyager Therapeutics Inc is functional in the United States biotechnology industry. Its focus lies in the research and development of gene therapies for the cure of severe diseases of the central nervous system such as the Parkinson's, Huntington's and Alzheimer's disease. The company has developed products such as VY-AADC01 for Advanced Parkinson's Disease, VY-HTT01 for Huntington's Disease. Voyager's sole source of revenue is generated through its collaboration with a company called Genzyme. Genzyme funds the collaboration for the multiple gene therapy programs, including programs for Parkinson's disease, Friedreich's ataxia, and Huntington's disease, as well as other CNS disorders.

Top Ranked Articles about Voyager Therapeutics Inc

Voyager Therapeutics Appoints Robert Hesslein as General Counsel
Voyager Therapeutics to Appoint Omar Khwaja, M.D., Ph.D., as Chief Medical Officer
Voyager Therapeutics Provides Updates for VY-AADC Clinical Program for Parkinson’s Disease
Voyager Therapeutics Joins Michael J. Fox Foundation Initiatives and Education Campaigns to Accelerate the Development of New therapies and a Cure for Parkinson’s Disease
Voyager Therapeutics Announces First Patient Dosed in RESTORE-1, a Phase 2 Trial of VY-AADC Gene Therapy for the Treatment of Parkinson’s Disease
Voyager Therapeutics Enters into Strategic Manufacturing Collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies
Voyager Therapeutics Announces Positive Longer-Term Data for VY-AADC for Parkinson’s Disease
Voyager Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Highlights
Voyager Therapeutics to Host Third Quarter 2018 Financial Results and Corporate Highlights Conference Call
Voyager Therapeutics Announces Preclinical Data for Huntington’s Disease and Amyotrophic Lateral Sclerosis Programs at the Congress of the European Society of Gene and Cell Therapy

Ratios

vs
industry
vs
history
PB Ratio 4.04
VYGR's PB Ratio is ranked lower than
70% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. VYGR: 4.04 )
Ranked among companies with meaningful PB Ratio only.
VYGR' s PB Ratio Range Over the Past 10 Years
Min: 1.43  Med: 2.73 Max: 9.86
Current: 4.04
1.43
9.86
PS Ratio 46.66
VYGR's PS Ratio is ranked lower than
86% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. VYGR: 46.66 )
Ranked among companies with meaningful PS Ratio only.
VYGR' s PS Ratio Range Over the Past 10 Years
Min: 9.55  Med: 28.85 Max: 252.86
Current: 46.66
9.55
252.86
EV-to-EBIT -0.97
VYGR's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. VYGR: -0.97 )
Ranked among companies with meaningful EV-to-EBIT only.
VYGR' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.2  Med: -2.9 Max: -0.4
Current: -0.97
-14.2
-0.4
EV-to-EBITDA -1.00
VYGR's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. VYGR: -1.00 )
Ranked among companies with meaningful EV-to-EBITDA only.
VYGR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.5  Med: -2.95 Max: -0.4
Current: -1
-14.5
-0.4
EV-to-Revenue 15.59
VYGR's EV-to-Revenue is ranked lower than
79% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. VYGR: 15.59 )
Ranked among companies with meaningful EV-to-Revenue only.
VYGR' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.8  Med: 15.3 Max: 225.7
Current: 15.59
0.8
225.7
Current Ratio 6.08
VYGR's Current Ratio is ranked higher than
65% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. VYGR: 6.08 )
Ranked among companies with meaningful Current Ratio only.
VYGR' s Current Ratio Range Over the Past 10 Years
Min: 3.38  Med: 8.19 Max: 14.56
Current: 6.08
3.38
14.56
Quick Ratio 6.08
VYGR's Quick Ratio is ranked higher than
66% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. VYGR: 6.08 )
Ranked among companies with meaningful Quick Ratio only.
VYGR' s Quick Ratio Range Over the Past 10 Years
Min: 3.38  Med: 8.19 Max: 14.56
Current: 6.08
3.38
14.56

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -29.00
VYGR's 3-Year Average Share Buyback Ratio is ranked lower than
73% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. VYGR: -29.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VYGR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -29  Med: -14.5 Max: 0
Current: -29
-29
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.51
VYGR's Price-to-Net-Cash is ranked lower than
59% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. VYGR: 5.51 )
Ranked among companies with meaningful Price-to-Net-Cash only.
VYGR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.58  Med: 3.88 Max: 12.7
Current: 5.51
1.58
12.7
Price-to-Net-Current-Asset-Value 5.20
VYGR's Price-to-Net-Current-Asset-Value is ranked lower than
61% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. VYGR: 5.20 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
VYGR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.56  Med: 3.8 Max: 11.97
Current: 5.2
1.56
11.97
Price-to-Tangible-Book 4.04
VYGR's Price-to-Tangible-Book is ranked lower than
62% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. VYGR: 4.04 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
VYGR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.43  Med: 3.18 Max: 9.32
Current: 4.04
1.43
9.32
Price-to-Median-PS-Value 1.62
VYGR's Price-to-Median-PS-Value is ranked lower than
93% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. VYGR: 1.62 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VYGR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.33  Med: 1.02 Max: 5.49
Current: 1.62
0.33
5.49
Earnings Yield (Greenblatt) % -102.89
VYGR's Earnings Yield (Greenblatt) % is ranked lower than
74% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. VYGR: -102.89 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VYGR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -265  Med: -34.3 Max: -7
Current: -102.89
-265
-7

More Statistics

Revenue (TTM) (Mil) $5.61
EPS (TTM) $ -2.43
Beta2.71
Volatility74.82%
52-Week Range $7.89 - 31.91
Shares Outstanding (Mil)32.56

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 8 11 20 21
EBIT (Mil $) -90 -100 -145 -152
EBITDA (Mil $) -93 -113 -127 -118
EPS ($) -2.86 -3.30 -3.13 -2.41
EPS without NRI ($) -2.86 -3.30 -3.13 -2.41
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}